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IMPACT OF ZINC SUPPLEMENTATION ONMENTAL AND PSYCHOMOTOR
SCORES OF CHILDREN AGED 12 TO 18 MONTHS: A RANDOMIZED,
DOUBLE-BLIND TRIAL
SUNITA TANEJA, PHD, NITA BHANDARI, PHD, RAJIV BAHL, PHD, AND MAHARAJ KISHAN BHAN, MD
Objective To evaluate the effect of zinc supplementation on mental and psychomotor scores in children aged 12 to
18 months.
Study design In this double-blind, randomized, placebo-controlled trial, children aged 6 to 30 months received daily
elemental zinc (10 mg for infants and 20 mg for others) or placebo for 4 months. Bayley Scales of Infant Development II were
used for development assessment in the 12- to 18-month subgroup at enrollment and the end of the study.
Results At the end of the study, the adjusted mean mental (P = .36) and psychomotor (P = .28) index scores were similar in
the intervention and control groups. In a multivariate model, the baseline mental development index score was positively
associated with the mother’s schooling, the child’s height for age, packed cell volumes, hospital birth, and attendance at a day
care center, and was negatively associated with the child’s age. Breastfeeding, the child’s weight for height, and packed cell
volumes were positively associated with the baseline psychomotor index score.
Conclusion Zinc supplementation did not affect the mental or psychomotor development index scores in a setting in which
zinc deficiency is common. (J Pediatr 2005;146:506-11)
Zinc deficiency is common in developing countries because of diets rich in phytate and fiber, a low intake of animal foods,and intestinal zinc losses during diarrheal illnesses.1,2 Zinc supplementation reduces the incidence of pneumonia anddiarrhea, and improves length gain in preschool years.2-4 The relationship between zinc deficiency and cognition is less
clear. Zinc deficiency during rapid brain growth or during the juvenile and adolescent period is reported to affect cognitive
development.5,6 The role of zinc in cognition in infants is biologically plausible. The high concentrations of zinc in the synaptic
vesicles of the special ‘‘zinc containing’’ neurons in the forebrain, with its function in biochemical processes like myelination and
the release of neurotransmitters like gamma-amino butyric acid and glutamate, suggest
that it may be a modulator of neuronal excitability.7 In a setting in which malnutrition and
zinc deficiency are common, we conducted a randomized, placebo-controlled trial in
children aged 6 months to 30 months in a low-income community to determine the impact
of daily zinc supplementation on diarrhea and pneumonia and, in the subgroup of trial
subjects aged 12 to 18 months at enrollment, on mental and psychomotor development.
We chose the 12- to 18-month age group because zinc deficiency is very common at this
age and the tools for development assessment are more robust than in earlier months of
life. The findings related to diarrhea, pneumonia, and plasma zinc levels have been
previously reported.8,9 We report here the findings related to mental and psychomotor
development.
METHODS
Study Setting
The setting and details of the methods have been previously published.8,9 The trial
was conducted in the urban community of Dakshinpuri in New Delhi, which has 15,000
dwellings and 75,000 inhabitants. Childhood malnutrition, zinc deficiency, diarrhea, and
lower respiratory tract infections are common in this setting.10-12
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Randomization and Blinding
Children were included when parental informed written
consent was available. Eligible children for the main study
were individually randomized by using a simple randomization
scheme in blocks of 8. The randomization scheme was
generated by a statistician at the Statens Serum Institute, who
was not otherwise involved with this study, using SAS
software (version 8.1; SAS Institute, Cary, NC). Zinc or
placebo syrups, similar in appearance and taste, were prepared
and packaged in unbreakable bottles by GK Pharma Aps,
Koge, Denmark; they also labeled bottles with unique child
identification numbers according to the randomization
scheme. Six bottles, 1 for each of the 4 study months and 2
extra, per child were produced and labeled before enrollment
commenced.
Enrollment and Intervention Delivery
Children aged 6 to 30 months were identified through
a door-to-door community survey. We excluded children for
non-consent, when they were planning to move within the
next 4 months, when they required hospitalization on the
enrollment day, or when they had received a massive dose of
vitamin A within 2 months. Information was obtained on the
socioeconomic characteristics of the family, the child’s feeding
practices, recent morbidity experience, birth weight, access to
television, and consumption of alcohol by the father. Diarrhea
and lower respiratory tract morbidity were monitored after
randomization in all enrolled children, as described pre-
viously.8,9 Development assessments at enrollment and study
end were limited to children aged 12 to 18 months at
enrollment.
Zinc was supplemented as zinc gluconate, with daily
doses of 10 mg (6 mL) of elemental zinc for infants and 20 mg
(12 mL) for older children for 4 months by a study attendant.
One bottle containing 250 mL was kept in the child’s home
and replaced monthly. Immunizations and treatment for acute
illnesses were provided at the study clinic as per the World
Health Organization guidelines.13 The study was approved by
the All India Institute of Medical Sciences ethics committee.
Informed verbal consent from community leaders and written
consent from parents was obtained, and a copy of the form was
left with the family.
Sample Size Calculations
Sample sizes were estimated with data from develop-
ment assessment practice sessions conducted in the same area.
Using value of a as 0.05 (95% confidence) and that of b as 0.1
(90% power) to detect a 5% improvement in the mean mental
development score and in the mean psychomotor development
score, 105 and 204 children, respectively, were required to be
enrolled per group. To allow for about 20% attrition, we
assessed mental and psychomotor development in 250
children per cell.
Development Assessments
Mental and psychomotor development scores were
assessed at enrollment and 4 months after supplementationImpact Of Zinc Supplementation On Mental And Psychomotor Scores Of Chil
Aged 12 To 18 Months: A Randomized, Double-Blind Trialwith the Bayley Scales of Infant Development II, strictly
according to the instruction manual.14 Children were tested in
the presence of their mothers at the clinic. When the child was
uncooperative, crying, or sleepy during the assessment, the test
was abandoned and the child was re-assessed the next day.
Three attempts on different days were made before the child
was labeled as uncooperative. Children who were sick at the
time of assessment were treated and tested after recovery.
Assessmentswere done in awell-lit, ventilated room, free
of distractions. Rapport was established with the child, and the
assessment was initiated only when the child was comfortable.
The chronological age was first estimated by subtracting the
date of birth from the date of testing. For premature births, the
months and days by which the child was premature were
subtracted from the chronological age to compute the corrected
age. Children were given credits for administered items only
when they were able to complete them.14
The Bayley Scales II were administered by the author
and a clinical psychologist, who were both trained. After
several practice sessions, standardization exercises were
conducted in 100 children. Ten children were assessed on
a day, independently by the 2 assessors with a 1-hour interval
between the 2 assessments; these exercises were completed
within 10 days.
Interobserver agreement during the study was ascer-
tained by testing in duplicate, 10% of the baseline and end
study assessments and correlating the mental developmental
index and psychomotor developmental index score obtained by
the first and the second assessor with the Kappa statistic
(mental development index Kappa = 0.88; psychomotor de-
velopment index Kappa = 0.86).15
Plasma Zinc
Blood samples were collected in all children at baseline
and for 30% of randomly selected children at study end for the
analysis of plasma zinc and copper levels and packed cell
volume. The methods and results for these samples have
previously been published.8,9
Data Management and Analysis
Double data entry followed by validation was completed
within 48 hours of filling out the form in the field. A child’s raw
scores on themental and psychomotor scales were computed by
adding the total number of items for which the child received
credit on each of the scales. The raw mental and psychomotor
scores were converted into age-adjusted index scores with US
norms.14 Mean mental and psychomotor development scores
were compared between groups with the Student t test.
A regression analysis was performed to adjust the effect
of zinc on mental and psychomotor scores for selected baseline
characteristics. For this, the effect of each baseline factor was
determined on the regression coefficients of zinc/placebo
treatment on the end study mental and psychomotor scores in
multiple linear regression models with 2 independent variables
(ie, treatment assignment and the characteristic). The factors
that changed the crude coefficient by $10 percent were
included in the final model to provide estimates of zincdren
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Figure. Trial profile of the main study with outcomes of diarrhea and pneumonia and the substudy on development assessments.treatment adjusted for potential confounders, and the adjusted
and unadjusted results are presented. For mental development
scores, the baseline characteristics in the model included
baseline mental index score, packed cell volume, age in
months, father’s alcohol consumption, and years of schooling
of parents. In the case of psychomotor development scores, the
explanatory variables in the model included baseline psycho-508 Taneja et almotor index score, height for age, packed cell volume, and
years of schooling of parents.
Additionally, a secondary analysis was performed to
identify covariates associated with baseline mental and
psychomotor scores with multiple regression. All factors that
were significantly (P <.05) associated with the outcome in the
univariate analysis were included in the model in addition toThe Journal of Pediatrics  April 2005
age as an explanatory variable. Analyses were conducted
with Stata software, version 6 (Stata Corp, Union Station,
Tex).
RESULTS
A total of 3802 children aged 6 to 30 months were
available through the door-to-door survey. Of these, 2482
were randomized (Figure). Those children who were12 to 18
months old at enrollment were subselected for baseline and
end-study mental and psychomotor assessment, 327 in the
zinc group and 323 in the placebo group. Of these, 283
(86.5%) in the zinc group and 288 (89.2%) in the placebo
group were available for end-study assessments (Figure).
Baseline Characteristics
The children in the 2 groups were similar for most
variables, but there were a significantly higher proportion of
children in the zinc group whose mothers (P = .07) and
fathers (P = .004) were literate (Table I). At baseline, there
was a significant difference between the mental develop-
ment index scores of the zinc and placebo groups (P = .0009),
but the psychomotor development scores were similar
(P = .12).
As reported previously, 45% of the study subjects had
low plasma zinc levels at enrollment, and the end-study mean
serum zinc level was significantly higher in the zinc group than
in the placebo group.8,9
End Study Mental and Psychomotor Development
Index Scores
After 4 months of supplementation, the mean mental
development index was similar in the intervention and placebo
groups (P = .09; Table II). The mean psychomotor de-
velopment index (P = .12) was similar in the 2 study groups
(Table II). There was no interaction between baseline zinc
status and the effect of zinc supplementation on the end-study
mean mental development index or psychomotor development
index16 (P = .5 for psychomotor and P <.5 >.2 for mental index
scores). Zinc supplementation, therefore, did not have
a differential effect among subjects who were zinc deficient
at baseline.
Factors Associated with Baseline Mental
and Psychomotor Index Scores
The child’s age was negatively associated with the
mental development scores, and the mother’s years of
schooling, height for age, packed cell volume, birth at hospital,
and attendance at the village Anganwadi (a daycare facility for
children aged <6 years, where a daily dietary supplement is also
given) were positively associated with the mental development
scores. For the psychomotor development index scores,
a positive association was found with breastfeeding, weight
for height, height for age, and packed cell volume, and
a negative association was found with the age of the child.
Zinc had no significant effect on the mental (P = .35) orImpact Of Zinc Supplementation On Mental And Psychomotor Scores Of Child
Aged 12 To 18 Months: A Randomized, Double-Blind Trialpsychomotor development index score (P = .28) after adjust-
ment for several potential confounding factors (Table III).
DISCUSSION
Optimizing intakes of zinc did not lead to improved
mental or motor development scores in this study. Some
limitations of the study need consideration. Assessments were
done only in the 12- to 18-month age subgroup of children.
This could potentially have resulted in baseline differences in
the intervention and control groups, and although the
intervention effects were adjusted for potential confounding
factors, there may be others that were not measured. Although
the Bayley Scales II were developed and standardized on the
basis of a sample representative of a US population, we believe
that for the purpose of comparing the impact of zinc versus
placebo on cognition, this instrument is valid.
The findings on mental development are consistent with
earlier randomized trials in which zinc was supplemented
during early infancy.17,18 In another trial, in which term
infants were supplemented with zinc for 5 months, the mental
development score was lower in the zinc group than in the
Table I. Baseline characteristics of children aged 12
to 18 months whose baseline and end-study mental
and psychomotor assessments were done with the
Bayley Scales of Infant Development
Characteristic
Zinc
n = 283
Placebo
n = 288
Age (months) at enrollment 14.8 ± 1.8 15.0 ± 2.0
Males, n (%) 155 (54.8) 152 (52.8)
Breastfed, n (%) 205 (72.8) 216 (75.0)
Number of family members 5.9 ± 2.5 5.9 ± 2.3
Working mothers, n (%) 29 (10.3) 17 (5.9)
Years of schooling of mothers 6.2 ± 4.6 5.2 ± 4.4
Years of schooling of fathers 9.0 ± 4.0 8.2 ± 4.0
Annual family income in
Indian rupees
36000 36000
(median, interquartile range) (24000–60000) (24000–60000)
Weight (kg) 8.3 ± 1.0 8.2 ± 1.1
Length (cm) 73.6 ± 3.4 73.5 ± 3.7
Proportion; n (%) of children with
Height for age z-score ,-2 98 (34.6) 112 (38.9)
Weight for height z-score ,-2 51 (18.0) 60 (20.8)
Weight for age z-score ,-2 151 (53.3) 172 (59.7)
Packed cell volume (%) 32.8 ± 3.1 32.2 ± 3.4
Birth weight 2.7 ± 0.6 2.6 ± 0.7
Index score Mental 101.2 ± 11.4 98.2 ± 11.0
Index score Psychomotor 99.8 ± 14.3 98.0 ± 14.4
Had television at home, n (%) 251 (88.7) 265 (92.0)
Children attending Anganwadi
center, n (%)
9 (3.2) 11 (3.8)
Father consumed alcohol, n (%) 138 (49.1) 146 (50.9)
All values are mean ± SD unless specified.ren
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Table II. Adjusted and unadjusted end-study mental and psychomotor scores of children aged 12 to 18 months
Characteristics
Zinc
n = 283
Placebo
n = 288
Difference in means or
difference in proportions (95% CI)* P-value
Mental Development
Mean (SD) index score 92.8 (10.9) 91.3 (10.8) 1.5 (-0.3 to 3.3) .358
-0.7 (-2.1 to 0.8)y
Psychomotor Development
Mean (SD) index score 93.9 (11.8) 92.2 (11.4) 1.6 (-0.4 to 3.6)
0.8 (-0.7 to 2.3)z .284
*All estimates are unadjusted, except those marked with y and z, which are values after adjusting for potential confounders.
yAdjusted effects in multiple linear regression models adjusted for baseline mental index score, packed cell volume, age in months, father consuming alcohol,
and years of schooling of parents. Model R square = 40%.
zAdjusted effects in multiple linear regression models adjusted for baseline psychomotor index scores, age in months, height for age, packed cell volume, and
years of schooling of parents. Model R square = 39%.placebo group, although the effect was small.19 One of the 2
zinc supplementation trials in low birth-weight infants
showed significant improvement in motor development
with the Griffiths scale, but the other did not find such
an effect.17,18 Two trials in India and Guatemala found
significant improvement in the physical activity of infants aged
6 to 9 months who received zinc supplementation; in these
trials, activity was assessed with the time sampling observation
method.20,21 In a recent zinc supplementation trial conducted
among infants in India who were small for their gestational
age, no direct effects of zinc supplementation were seen on the
infants’ development or behavior.22
The conclusion from these studies is that zinc
supplementation in infants and young children in developing
countries failed to improve mental development. Although
Table III. Factors associated with baseline Mental
and Psychomotor Index Scores in multiple
regression models
Predictor variable Coefficient 95% CI P-value
Mental Development
Index Score*
Age (months) -2.21 -2.6–-1.80 0
Years of schooling of mother 0.48 0.29–0.67 0
Height-for-age Z Score 1.82 1.01–2.63 0
Baseline packed cell volume (%) 0.38 0.13–0.63 .003
Children born in hospital 2.21 0.50–3.92 .011
Children attending Anganwadi 4.51 0.09–8.94 .046
Psychomotor Development
Index Scorey
Age in months -0.94 -1.51–-0.37 .001
Children breast fed 3.43 0.87–5.98 .009
Weight-for-height Z-score 1.55 0.15–2.94 .030
Height-for-age Z-score 4.09 3.02–5.14 .000
Baseline packed cell volume (%) 0.57 0.23–0.92 .001
*Model R square = 27%.
yModel R square = 16%.510 Taneja et ala few studies found an impact on physical activity,20,21 the
implications of these benefits are unclear.
Our results confirm previous findings that low maternal
education level, stunting, and iron deficiency anemia are
associated with impaired mental and psychomotor index
scores. Children born in hospitals had better scores, which is
probably an indirect indicator of socioeconomic status.
Attendance at the day care facility was associated with higher
development index scores. This may be related to the
stimulation provided by the caregivers or peers or the
supplement provided to these children at the facility.
The decline in mental development index scores with an in-
fant’s age may be because existing care practices and other
environmental factors are inadequate, and these may worsen
during this period because of the cessation of breastfeeding
by most mothers and the increasing demands on the child
for interaction at this age. The importance of care practices is
also reflected in the positive association between a mother’s
education level, child’s height, and packed cell volume and the
psychomotor development scores. Weight for height was
directly related to the psychomotor scores, but not to the
mental development scores. Malnourished children, particu-
larly those who are wasted, are frequently described as
lethargic, possibly because they reduce their activity as
a protective strategy to conserve energy.
The lack of benefit of zinc on mental and psychomotor
index scores may have several explanations. There may truly be
no effect of zinc deficiency on cognition; 4 months may be
insufficient time for treatment effects to unfold; or zinc
deficiency may affect specific behaviors or processes that are
not detected with the Bayley Scales II.23 It is also possible that
the effect of zinc on mental and psychomotor development
may have been limited by its interaction with other trace
elements, such as iron, copper, folate, and possibly others.24
Zinc deficiency exists as a part of overall malnutrition and
in combination with other micronutrient deficiencies.
Concurrent supplementation with other limiting micronu-
trients may be necessary for the effect of zinc repletion to
manifest. Improving zinc intakes in developing countries, suchThe Journal of Pediatrics  April 2005
as India, is, however, a priority because of its effects on
diarrhea and respiratory infections.
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